Finding RNA-targeted cures for cancer
Curamir strives to improve patients’ lives by developing
transformative RNA-targeted life-changing oncology therapies

About Us

Curamir was founded in 2019 on the strength of over a decade of innovative research and development on microRNA and cancer by Professor Jingfang Ju of Renaissance School of Medicine, Stony Brook University

Platform / Technology

We are building an RNA-targeted technology platform with broad therapeutic potential.

In the near term, we are developing microRNA (miRNA) mimics to target resistant cancer stem-like cells with our patented platform technologies. Our unique modifications of miRNA provide enhancement to stability, efficacy, and ease of delivery.
The uniqueness of our miRNA-based drug discovery and development platform is that it creates chemically modified, multi-targeted RNA mimics, each of which impacts multiple targets and signaling pathways to achieve superior therapeutic activity by eliminating cancer cells.

Recent Announcements

Delos Capital Announces the Launch of Curamir Therapeutics Inc.

HONG KONG, Sept. 20, 2019 /PRNewswire/ — Delos Capital today announces that it has launched Curamir Therapeutics Inc., a Woburn, MA-based biotechnology company pioneering micro RNA (miRNA) based cancer therapeutics, with a $10 million Series A financing. Curamir is incubated through a licensing collaboration with the State University of New York (SUNY) and co-founded by veterans in

Read More »
Through a unique combination of deep domain expertise, global connections, experience building international partnerships and strong networks in global life sciences communities, Delos Capital searches the burgeoning therapeutics and Medtech marketplace for the most promising companies, then helps them open the doors to the future.